Vol. 17,No. 1,January 2010 Supplement Iron Overload in Myelodysplastic Syndromes: Diagnosis and Management

List A.F. . Iron overload in myelodysplastic syndromes: diagnosis and management. Cancer Control. 2010; 17(1 suppl): 2–8.

US Food and Drug Administration. Exjade® (deferasirox): early communication. September 25, 2009. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183840.htm. Accessed January 4, 2010.

Exjade® (deferasirox) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021882s010lbl.pdf. Accessed February 23, 2010.